CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion
Investor's Business DailyCymaBay stock skyrocketed Monday after Gilead Sciences announced it will buy it for $4.3 billion. CBAY stock surged almost 25%.
The post CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion appeared first on Investor's …